ABOS · Acumen Pharmaceuticals Inc
United States · RS rating 2 · As of 2026-11-03
| Price | 0.23 USD |
|---|---|
| 1-day change | -2.3% |
| RS rating (overall / 1M / 3M / 12M) | 2 / 1 / 2 / 5 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 12 / 15 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -36.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +93.0% |
| Market cap (USD) | $192.8M |